Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema
NCT ID: NCT01487629
Last Updated: 2011-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
53 participants
INTERVENTIONAL
2010-04-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bevacizumab
Treatment of macular edema with intravitreal Bevacizumab
Bevacizumab
Bevacizumab, 1.5 mg, intravitreal, throughout the study
Ranibizumab
Treatment of macular edema with intravitreal Ranibizumab
Ranibizumab
Ranibizumab, 0.5 mg, intravitreal, throughout the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Bevacizumab, 1.5 mg, intravitreal, throughout the study
Ranibizumab
Ranibizumab, 0.5 mg, intravitreal, throughout the study
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Best corrected visual acuity equal or worse than 20/40 and better than 20/800;
* Central subfield macular thickness greater than 300 µm
Exclusion Criteria
* High-risk proliferative diabetic retinopathy
* Previous treatment for DME in the past three months
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundação de Amparo à Pesquisa do Estado de São Paulo
OTHER_GOV
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rodrigo Jorge
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodrigo Jorge, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Sao Paulo
Felipe Almeida, MD
Role: STUDY_DIRECTOR
Hospital das Clinicas - Faculdade de Medicina de Ribeirão Preto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinics Hospital of Ribeirão Preto, School of Medicine of Ribeirão Preto, USP
Ribeirão Preto, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, Siqueira RC, Scott IU, Messias A, Jorge R. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013 Sep;156(3):502-510.e2. doi: 10.1016/j.ajo.2013.04.026. Epub 2013 Jun 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13368/2010
Identifier Type: -
Identifier Source: org_study_id